Myriad Genetics (MYGN) Misses Q2 EPS by 19c ; Offers Guidance

Myriad Genetics (NASDAQ: MYGN) reported Q2 EPS of ($0.25), $0.19 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $190.7 million versus the consensus estimate of $206.03 million.

GUIDANCE:

Myriad Genetics sees FY2026 revenue of $770-790 million, versus the consensus of $863.6 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

You May Also Be Interested In

• U.S. and Denmark close in on a Greenland deal - Reuters
• SmartKem (SMTK) files for 15.13M share offering by selling stockholders
• OpenAI's Sam Altman to brief the UN Security Council next week - Reuters